Cargando…

Effects of regorafenib on the mononuclear/phagocyte system and how these contribute to the inhibition of colorectal tumors in mice

BACKGROUND: Regorafenib was previously shown to reduce tumor-associated macrophages and potently inhibit colony-stimulating factor 1 receptor (CSF1R), also known as CD115, in biochemical assays. The CSF1R signaling pathway is essential in the biology of the mononuclear/phagocyte system, which can pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Grünewald, Sylvia, Stecklum, Maria, Rizzo, Manuel, Rathjens, Jonathan, Fiebig, Lukas, Zopf, Dieter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10069031/
https://www.ncbi.nlm.nih.gov/pubmed/37013652
http://dx.doi.org/10.1186/s40001-023-01099-2
_version_ 1785018779313373184
author Grünewald, Sylvia
Stecklum, Maria
Rizzo, Manuel
Rathjens, Jonathan
Fiebig, Lukas
Zopf, Dieter
author_facet Grünewald, Sylvia
Stecklum, Maria
Rizzo, Manuel
Rathjens, Jonathan
Fiebig, Lukas
Zopf, Dieter
author_sort Grünewald, Sylvia
collection PubMed
description BACKGROUND: Regorafenib was previously shown to reduce tumor-associated macrophages and potently inhibit colony-stimulating factor 1 receptor (CSF1R), also known as CD115, in biochemical assays. The CSF1R signaling pathway is essential in the biology of the mononuclear/phagocyte system, which can promote the development of cancer. METHODS: A deeper investigation of regorafenib’s effects on CSF1R signaling was performed using preclinical in vitro and in vivo studies with syngeneic CT26 and MC38 mouse models of colorectal cancer. Peripheral blood and tumor tissue were analyzed mechanistically by flow cytometry using antibodies against CD115/CSF1R and F4/80 and by ELISA for chemokine (C–C motif) ligand 2 (CCL2) levels. These read-outs were correlated with drug levels for the detection of pharmacokinetic/pharmacodynamic relationships. RESULTS: Potent inhibition of CSF1R by regorafenib and its metabolites M-2, M-4, and M-5 was confirmed in vitro in RAW264.7 macrophages. The dose-dependent growth inhibition of subcutaneous CT26 tumors by regorafenib was associated with a significant reduction in both the number of CD115(hi) monocytes in peripheral blood and the number of selective subpopulations of intratumoral F4/80(hi) tumor-associated macrophages. CCL2 levels were not affected by regorafenib in blood but increased in tumor tissue, which may contribute to drug resistance and prevent complete tumor remission. An inverse relationship between regorafenib concentration and the number of CD115(hi) monocytes and CCL2 levels was observed in peripheral blood, supporting the mechanistic involvement of regorafenib. CONCLUSIONS: These findings may be clinically useful in optimizing drug dosing using blood-based pharmacodynamic markers and in identifying resistance mechanisms and ways to overcome them by appropriate drug combinations. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40001-023-01099-2.
format Online
Article
Text
id pubmed-10069031
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-100690312023-04-04 Effects of regorafenib on the mononuclear/phagocyte system and how these contribute to the inhibition of colorectal tumors in mice Grünewald, Sylvia Stecklum, Maria Rizzo, Manuel Rathjens, Jonathan Fiebig, Lukas Zopf, Dieter Eur J Med Res Research BACKGROUND: Regorafenib was previously shown to reduce tumor-associated macrophages and potently inhibit colony-stimulating factor 1 receptor (CSF1R), also known as CD115, in biochemical assays. The CSF1R signaling pathway is essential in the biology of the mononuclear/phagocyte system, which can promote the development of cancer. METHODS: A deeper investigation of regorafenib’s effects on CSF1R signaling was performed using preclinical in vitro and in vivo studies with syngeneic CT26 and MC38 mouse models of colorectal cancer. Peripheral blood and tumor tissue were analyzed mechanistically by flow cytometry using antibodies against CD115/CSF1R and F4/80 and by ELISA for chemokine (C–C motif) ligand 2 (CCL2) levels. These read-outs were correlated with drug levels for the detection of pharmacokinetic/pharmacodynamic relationships. RESULTS: Potent inhibition of CSF1R by regorafenib and its metabolites M-2, M-4, and M-5 was confirmed in vitro in RAW264.7 macrophages. The dose-dependent growth inhibition of subcutaneous CT26 tumors by regorafenib was associated with a significant reduction in both the number of CD115(hi) monocytes in peripheral blood and the number of selective subpopulations of intratumoral F4/80(hi) tumor-associated macrophages. CCL2 levels were not affected by regorafenib in blood but increased in tumor tissue, which may contribute to drug resistance and prevent complete tumor remission. An inverse relationship between regorafenib concentration and the number of CD115(hi) monocytes and CCL2 levels was observed in peripheral blood, supporting the mechanistic involvement of regorafenib. CONCLUSIONS: These findings may be clinically useful in optimizing drug dosing using blood-based pharmacodynamic markers and in identifying resistance mechanisms and ways to overcome them by appropriate drug combinations. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40001-023-01099-2. BioMed Central 2023-04-03 /pmc/articles/PMC10069031/ /pubmed/37013652 http://dx.doi.org/10.1186/s40001-023-01099-2 Text en © The Author(s) 2023, corrected publication 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Grünewald, Sylvia
Stecklum, Maria
Rizzo, Manuel
Rathjens, Jonathan
Fiebig, Lukas
Zopf, Dieter
Effects of regorafenib on the mononuclear/phagocyte system and how these contribute to the inhibition of colorectal tumors in mice
title Effects of regorafenib on the mononuclear/phagocyte system and how these contribute to the inhibition of colorectal tumors in mice
title_full Effects of regorafenib on the mononuclear/phagocyte system and how these contribute to the inhibition of colorectal tumors in mice
title_fullStr Effects of regorafenib on the mononuclear/phagocyte system and how these contribute to the inhibition of colorectal tumors in mice
title_full_unstemmed Effects of regorafenib on the mononuclear/phagocyte system and how these contribute to the inhibition of colorectal tumors in mice
title_short Effects of regorafenib on the mononuclear/phagocyte system and how these contribute to the inhibition of colorectal tumors in mice
title_sort effects of regorafenib on the mononuclear/phagocyte system and how these contribute to the inhibition of colorectal tumors in mice
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10069031/
https://www.ncbi.nlm.nih.gov/pubmed/37013652
http://dx.doi.org/10.1186/s40001-023-01099-2
work_keys_str_mv AT grunewaldsylvia effectsofregorafenibonthemononuclearphagocytesystemandhowthesecontributetotheinhibitionofcolorectaltumorsinmice
AT stecklummaria effectsofregorafenibonthemononuclearphagocytesystemandhowthesecontributetotheinhibitionofcolorectaltumorsinmice
AT rizzomanuel effectsofregorafenibonthemononuclearphagocytesystemandhowthesecontributetotheinhibitionofcolorectaltumorsinmice
AT rathjensjonathan effectsofregorafenibonthemononuclearphagocytesystemandhowthesecontributetotheinhibitionofcolorectaltumorsinmice
AT fiebiglukas effectsofregorafenibonthemononuclearphagocytesystemandhowthesecontributetotheinhibitionofcolorectaltumorsinmice
AT zopfdieter effectsofregorafenibonthemononuclearphagocytesystemandhowthesecontributetotheinhibitionofcolorectaltumorsinmice